Sarcopenia Market Outlook 2034 - Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Sarcopenia Market Summary
The Sarcopenia market is currently largest in the US, valued at roughly USD 1,500 million in 2025, with growth expected through 2034. No approved pharmacological treatments exist; exercise remains the primary intervention, supplemented by nutrition, vitamin D, and hormone therapies. Sarcopenia, an age-related condition characterized by low muscle mass, strength, and physical function, affects approximately 25% of older adults and is closely associated with frailty. Prevalence varies by population, ranging from 18% in diabetic patients to 66% in individuals with unresectable esophageal cancer, and around 40% in patients with liver cirrhosis. According to EWGSOP and IWGS criteria, 1-29% of community-dwelling adults aged ≥65 and 14-33% of care facility residents meet the definition of sarcopenia. The therapeutic pipeline includes TNF-α inhibitors (MYMD-1), androgen receptor agonists (LPCN 1148), c-MAS-1 agonists (Sarconeos), GLP-1 receptor agonists (Froniglutide), and glycolytic pathway modulators (BPM 31510). Companies driving development include TNF Pharmaceuticals, Biophytis, Lipocine, and others, positioning the market for expansion.

DelveInsight's report, "Sarcopenia Market Insights, Epidemiology, and Market Forecast - 2034," provides a comprehensive analysis of Sarcopenia, including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report details current treatment approaches, emerging therapies, individual drug market shares, and the present and forecasted market size for Sarcopenia from 2020 to 2034 across seven major markets. Additionally, it examines treatment algorithms, market drivers and barriers, and unmet medical needs, highlighting opportunities and evaluating the overall growth potential within the Sarcopenia market.

Request for a Free Sample Report @ Sarcopenia Market Forecast - https://www.delveinsight.com/report-store/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the Key facts of Sarcopenia Market are:
• According to DelveInsight's analysis, sarcopenia market size in the 7MM is expected to grow at a significant CAGR by 2034.
• The total diagnosed prevalent cases of sarcopenia in the 7MM was 27.4 million cases in 2023 and this number is forecasted to climb at a significant CAGR in the research period (2020-2034).
• The sarcopenia market in the 7MM was valued at approximately USD 2.2 billion in 2024 and is expected to grow throughout 2025-2034.
• The US held the largest share in 2025, with a market size of around USD 1.5 billion, projected to rise by 2034.
• Diagnosed sarcopenia cases in the 7MM reached nearly 19.8 million in 2024, with an upward trend forecasted through 2034.
• In the US, the highest sarcopenia prevalence in 2024 was among the 65-69 age group, with about 4.5 million diagnosed patients.Amongst the EU-5 countries, Italy had the highest number of cases followed by Germany with 3,556,282 and 3,194,532 cases respectively. Spain accounted for least number of sarcopenia cases in 2021.
• Japan accounted for 3,104,585 cases sarcopenia in 2021, which accounted for approximately 9% of the total 7MM prevalent cases of sarcopenia.
• According to DelveInsight, males are affected more as compared to females in case of sarcopenia.
• Emerging therapies for sarcopenia include MYMD-1/ Iisomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510, OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, and others.
• Key companies involved in the treatment of sarcopenia include MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Rejuvenate Biomed, Oncocross Therapeutics, OPKO health, NMD Pharma, Rubedo Life Sciences, Immunoforge, and others.
• In April 2025, TNF Pharmaceuticals, Inc. announced that a platform presentation of the abstract titled "Isomyosamine for the Treatment of Sarcopenia in Older Adults" was delivered by Mitchell Glass, M.D., President and Chief Medical Officer of TNF, at the British Geriatrics Society (BGS) Spring Meeting 2025, held April 9-11 in Belfast, Ireland, and online.
• In December 2024, Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track Designation to LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis. LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the POC study improved sarcopenia and associated clinical outcomes. LPCN 1148 is targeted to be a "First in Class" product candidate with a novel mechanism of action for management of cirrhosis.
• In December 2024, TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that significant positive topline results from a Phase 2a study of its lead drug candidate MYMD-1® (isomyosamine) was presented at a prestigious international congress of global experts in sarcopenia and related disorders held December 6-8, 2024 in Washington, D.C.
• In October 2024, Rejuvenate Biomed, in collaboration with the University of Leicester, the National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre (BRC), and Wellcome Leap Inc., has formalized an agreement to conduct a Phase 2 clinical trial targeting sarcopenia associated with chronic obstructive pulmonary disease (COPD).

Sarcopenia Overview
Sarcopenia is a progressive and generalized skeletal muscle disorder associated with aging and various chronic conditions. Sarcopenia leads to the loss of muscle mass, strength, and function, significantly impacting mobility, independence, and overall quality of life in older adults. Sarcopenia is often underdiagnosed but is increasingly recognized as a major public health concern due to the aging global population.

Sarcopenia is caused by multiple factors including hormonal changes, reduced physical activity, inflammation, poor nutrition, and mitochondrial dysfunction. Sarcopenia can be diagnosed through a combination of muscle strength assessments, physical performance tests, and muscle mass measurements using imaging techniques. Sarcopenia is closely linked to increased risks of falls, fractures, hospitalization, and mortality.

Sarcopenia management focuses on resistance training, protein-rich diets, and potential pharmacological interventions. Sarcopenia treatment strategies also explore anabolic agents, myostatin inhibitors, and hormonal therapies under clinical investigation. Sarcopenia awareness and early intervention are essential to prevent disability and improve the functional outcomes in at-risk populations.
Sarcopenia guidelines by international organizations emphasize standardized diagnostic criteria and individualized care plans. Sarcopenia research is rapidly evolving, aiming to discover novel biomarkers and therapies. Sarcopenia, as a distinct medical condition, highlights the need for multidisciplinary approaches to enhance aging-related health outcomes.

Learn more about Sarcopenia treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Sarcopenia Prevalence - https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sarcopenia Market Outlook
The 7MM sarcopenia market was valued at approximately USD 2,200 million in 2024 and is projected to grow through 2034. Among EU4 and the UK, the UK had the largest market in 2024, while Spain ranked lowest. Supportive care is expected to generate the highest revenue by 2034, reflecting ongoing reliance on non-pharmacological interventions.

Currently, sarcopenia management relies on nutritional interventions, physical therapy, and lifestyle modifications, with no approved pharmacological therapies. Treatments aim to preserve or restore muscle mass and function, improve quality of life, and reduce risks such as falls and fractures. Nutritional supplements, vitamin D, and, in select cases, hormone therapies may be used, though steroid hormones carry notable side effects. The clinical pipeline remains limited, with promising candidates including TNF Pharmaceuticals' MYMD-1, Lipocine's LPCN 1148, and Biophytis' BIO101.

Sarcopenia Epidemiology
Sarcopenia epidemiology segmented by total diagnosed prevalent cases of sarcopenia, gender-specific diagnosed prevalent cases of sarcopenia, age-specific diagnosed prevalent cases of sarcopenia, and severity-specific diagnosed prevalent cases of sarcopenia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan from 2020 to 2034.

Total Diagnosed Cases
In 2024, the total diagnosed prevalent cases of sarcopenia in the 7MM were approximately 19,836,200, with projections indicating continued growth through 2034. Among EU4 and the UK, the UK had the highest number of diagnosed cases, followed by Germany, while Spain reported the lowest.

Severity Segmentation
Sarcopenia cases are classified as mild-to-moderate and severe. Mild-to-moderate cases represented the largest patient group in the US in 2024.

Age Segmentation
In the US, cases are stratified by age groups: 65-69 years, 70-79 years, and ≥80 years. The 65-69-year age group accounted for the highest number of patients (~4,520,200) in 2024. In Japan, diagnosed cases totaled approximately 5,225,100.

Gender Segmentation
In the US, males had a higher prevalence of sarcopenia compared to females in 2024.

Explore more about Sarcopenia Epidemiology @ Sarcopenia Market Dynamics - https://www.delveinsight.com/report-store/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sarcopenia Pipeline Outlook and Drugs Uptake
This section focuses on the uptake rate of the potential Sarcopenia drugs recently launched in the Sarcopenia market or expected to be launched in 2020-2034. The analysis covers the Sarcopenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

MYMD-1/Isomyosamine: TNF Pharmaceuticals
MYMD-1 is an oral, first-in-class TNF-α inhibitor being developed for conditions linked to immune-metabolic dysregulation, including sarcopenia, autoimmune diseases, and aging-related decline. In 2023, a Phase II study demonstrated its safety and efficacy in sarcopenia, showing significant reduction in TNF-α and inflammation without the need for injections or infusions. Following positive Phase IIa results presented in December 2024, TNF Pharmaceuticals plans to initiate a Phase III trial. Key safety milestones achieved in January 2025 support expanded long-term studies. If approved, MYMD-1 could become the first FDA-approved therapy for sarcopenia.

LPCN 1148: Lipocine
LPCN 1148, an oral prodrug of bioidentical testosterone, is under investigation in a Phase II Proof-of-Concept study in patients with decompensated cirrhosis. The therapy demonstrated improvements in sarcopenia and related clinical outcomes. Lipocine is planning Phase III trials, positioning LPCN 1148 as a potential first-in-class treatment with a novel mechanism for sarcopenia management in cirrhosis patients.

Some of the Sarcopenia companies and therapies:
• TNF Pharmaceuticals - MYMD-1 / Isomyosamine
• Lipocine - LPCN 1148
• Biophytis - Sarconeos (BIO101)
• ImmunoForge - Froniglutide (PF-1801)
• Rejuvenate Biomed - RJx-01
• Keros Therapeutics - KER-065
• BPGbio - BPM 31510 (ubidecarenone)
• Oncocross - OC514
• Mirscience Therapeutics - MT29
• Turn Biotechnologies - TRN-005
• NMD PHARMA - NMDP-05
• ImmunoForge - PF1807
• Dong Wha PHARM - DW1030

Request for a sample report to understand more about the Sarcopenia pipeline development activities @ Sarcopenia Treatment Market - https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sarcopenia Therapeutics Assessment
Major key companies are working proactively in the Sarcopenia Therapeutics market to develop novel therapies which will drive the Sarcopenia treatment markets in the upcoming years are MyMD Pharmaceuticals (NASDAQ: MYMD), Biophytis (EPA: ALBPS), OPKO Health (NASDAQ: OPK), Dystrogen Therapeutics, Rejuvenate Biomed, Oncocross Therapeutics, NMD Pharma, Rubedo Life Sciences, Immunoforge, and others

Learn more about the emerging Sarcopenia therapies & key companies @ Sarcopenia Clinical Trials and FDA Approvals - https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sarcopenia Report Key Insights
1. Sarcopenia Patient Population
2. Sarcopenia Market Size and Trends
3. Key Cross Competition in the Sarcopenia Market
4. Sarcopenia Market Dynamics (Key Drivers and Barriers)
5. Sarcopenia Market Opportunities
6. Sarcopenia Therapeutic Approaches
7. Sarcopenia Pipeline Analysis
8. Sarcopenia Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Sarcopenia Market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.